Anzeige
Mehr »
Login
Freitag, 26.04.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Geheimtipp: Rasanter Aufstieg, Branchenrevolution und Jahresumsatz von 50 Mio. $
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
447 Leser
Artikel bewerten:
(2)

Amsterdam UMC adds digital pathology to its existing Sectra solution to enable integrated diagnostics for better cancer care

LINKÖPING, Sweden, Jan. 21, 2021 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra (STO: SECT B) has received an order for its digital pathology solution from Amsterdam UMC in the Netherlands. This follows a recently announced radiology imaging contract. With radiology and pathology in one joint solution, Amsterdam UMC will be able to conveniently share images and information between the two medical specialties, enabling efficient integrated diagnostics and improved patient-centric care.

"It's exciting to see how Amsterdam UMC, in just a short time, has taken these steps toward radiology and pathology efficiency, regional collaboration and integrated diagnostics. I'm confident that our experience and vendor-neutral platform will contribute to their adoption of emerging technologies, such as AI, in the future," says Peter Osinga, Managing Director of Sectra Benelux.

One of the main benefits of digitizing pathology is the ability to share digital images, rather than sending physical slides back and forth. This helps healthcare providers reduce treatment errors as well as logistics and administration, resulting in potential savings. Access to specialists for efficient external readings and second opinions can also cut waiting times for patients-helping pathology to meet patient demand and regulatory enforcements.

Sectra's digital pathology solution will be integrated with the laboratory information system (LIS) used at Amsterdam UMC. This will provide pathologists with a complete overview of the patient history in one application and enable workflow orchestration to drive the workflow according to sub-specialties, rules and priorities. The solution's vendor-neutral approach also enables Amsterdam UMC to use the scanner vendor of its choice.

The contract was signed during the third quarter of Sectra's fiscal year 2020/2021.

Sectra's pathology solution is part of its enterprise imaging offering, which provides a unified strategy for all imaging needs while lowering operational costs. The scalable and modular enterprise imaging solution, with a VNA at its core, allows healthcare providers to grow from ology to ology and from enterprise to enterprise. Read more about Sectra's enterprise imaging solution and why Sectra PACS is ranked "Best in KLAS" for seven consecutive years at medical.sectra.com.

About Sectra
Sectra assists hospitals throughout the world to enhance the efficiency of care, and authorities and defense forces in Europe to protect society's most sensitive information. Thereby, Sectra contributes to a healthier and safer society. The company was founded in 1978, has its head office in Linköping, Sweden, with direct sales in 19 countries, and operates through partners worldwide. Sales in the 2019/2020 fiscal year totaled SEK 1,661 million. The Sectra share is quoted on the Nasdaq Stockholm exchange. For more information, visit https://sectra.com/.

For further information, please contact:
Dr. Torbjörn Kronander, CEO and President Sectra AB, +46 (0)705 23 52 27
Marie Ekström Trägårdh, Executive Vice President Sectra AB and President Sectra Imaging IT Solutions, +46 (0)708 23 56 10

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/sectra/r/amsterdam-umc-adds-digital-pathology-to-its-existing-sectra-solution-to-enable-integrated-diagnostic,c3271221

The following files are available for download:

https://news.cision.com/sectra/i/pathology-screen,c2869265

Pathology_Screen

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2021 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.